Used primarily in pharmaceutical research and development, this compound serves as a key intermediate in the synthesis of immunomodulatory drugs. It is notably involved in the production of analogs related to thalidomide and lenalidomide, which are used in the treatment of multiple myeloma and other hematological cancers. Its structure supports enhanced biological activity by promoting protein-protein interactions and influencing cytokine modulation. Additionally, it is explored for use in targeted protein degradation technologies, such as PROTACs, due to its ability to bind cereblon, an E3 ubiquitin ligase. This property makes it valuable in developing novel therapeutics for cancer and inflammatory diseases.